Alto Neuroscience (ANRO)

• Market cap: $547M
• 1 day: 3.86%
• 5 days: 10.04%
• 1 month: 10.17%
• 3 months: 37.59%
• 6 months: 364.47%
• Year to date: 10.31%
• 1 year: 488.42%
• 5 years: -11.59%
• 10 years: -11.59%
• Sector: Healthcare
• Industry: Biotechnology

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 76